Bone Biologics (Nasdaq:BBLG) announced today that it priced an underwritten public offering worth $51. million. The offering includes nearly 3.8 million units of securities. Each unit costs $1.35. The gross proceeds total $5.1 million before deducting underwriting discounts and commissions, plus other offering expenses. Each unit features one share of common stock. They also include […]
Bone Biologics Corp.
Bone Biologics raises another $6m
Bone Biologics (OTC:BBLG) said today that it raised another $5.9 million for the orthobiologics it makes for spinal fusion procedures. The round includes $3.9 million in equity and a $2 million credit facility, the Burlington, Mass.-based company said. Bone Biologics said it plans to use the proceeds for working capital, protein development and regulatory and clinical […]
Bone Biologics closes $5.8m round
Regenerative orthobiologic company Bone Biologics said it recently closed a $5.75 million round joined by the Musculoskeletal Transplant Foundation, Orthofix (NSDQ:OFIX) and Hankey Capital to support development of its bone graft substitute. Boston-based Bone Biologics is developing Nell-1, a bone growth factor designed to be an alternative to other bone growth factors used in surgical procedures such […]
NeuSpera Medical lands ex-Cyberonics R&D SVP Morris for CEO | Personnel Moves
NeuSpera Medical said it snagged the former R&D senior vice president at Cyberonics, Milton Morris, for its corner office as it gears up to raise a Series A round for its neuromodulation technology. NeuSpera, formerly known as Vivonda Medical, is developing injectable neuromodulation devices, so called “electroceuticals,” using licensed mid-field powering technology. The Santa Clara, […]
